Here's how tesamorelin vs sermorelin and other GHRH peptides compare: GHRH Peptide Comparison Table Property Tesamorelin Sermorelin CJC-1295 (No DAC) CJC-1295 DAC FDA Status FDA Approved (Egrifta) Previously approved, now discontinued Not approved Not approved Amino Acids 44 (modified GHRH) 29 (GHRH 1-29) 29 + modifications 29 + Drug Affinity Complex Half-Life ~26-38 minutes ~10-20 minutes ~30 minutes ~6-8 days Mechanism GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist GHRH receptor agonist (extended) Clinical Trial Data Extensive (Phase 3 completed) Limited (older studies) Limited (Phase 1/2) Limited Primary Research Use Lipodystrophy, NAFLD, body composition GH deficiency research GH axis research Extended GH release research Key Differentiators Tesamorelin's advantages: Only GHRH analog with current FDA approval Extensive Phase 3 clinical trial data Documented efficacy for visceral fat reduction Well-characterized safety profile from prescription use Sermorelin note: Previously FDA-approved (1997) for pediatric growth hormone deficiency but discontinued by manufacturers no longer available as a prescription product in the US
BPC-157 can survive the digestive environment and interact with cells in the gastrointestinal tract, promoting mucosal repair, angiogenesis, and anti-inflammatory effects that accelerate healing of ulcers, lesions, and intestinal injuries when administered orally
Developed by Eli Lilly, it is a single-molecule triple receptor agonist targeting three key metabolic hormone receptors simultaneously: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon
This compounds across multiple exposures, which is why strict cold chain discipline matters from the moment of reconstitution
Lipotropic injections typically contain methionine, inositol, choline, and L-carnitine, but lack high-quality randomised controlled trial evidence for weight loss
Is particularly suitable for the treatment of respiratory issues, asthma, neurological function, pulmonary fibrosis
